Abstract
DA-8159, a new Phosphodiesterase (PDE) 5 inhibitor, has exhibited potent erectogenic potential in a penile erection test in rats and anesthetized dogs. In this study, we investigated the mechanism of its erectogenic activity by measuring the activity of DA-8159 against a various PDE isozymes and assessing cGMP and cAMP formation in a rabbit corpus cavernosumin vitro. DA-8159 inhibited the PDE 5 activity in rabbit and human platelets, which the IC50 was 5.84± 1.70 nM and 8.25± 2.90 nM, respectively. The IC50 of DA-8159 on PDE 1, PDE2, PDE 3 and PDE 6 were 870±57.4 nM, 101 ± 15 μM, 52.0±3.53 μM and 53.3±2.47 nM, respectively. This suggests that DA-8159 is a potent, highly selective, competitive inhibitor of PDE 5-catalyzed cGMP hydrolysis. The rates of cGMP hydrolysis catalyzed by human platelets-derived PDE 5 as a function of the cGMP concentration (5~100 nM) and two-fixed DA-8159 concentration (11.3 and 18.8 nM) were investigated in order to characterize the mode of PDE 5 inhibition by DA-8159. DA-8159 increased the apparent Km value for cGMP hydrolysis but had no effect on the apparent Vmax, indicating a competitive mode of inhibition. DA-8159 increased the cGMP concentrations in the rabbit corpus cavernosum dose dependently. In the presence of sodium nitroprusside (SNP), DA-8159 significantly stimulated the accumulation of cGMP when compared to the control level. This indicated that the enhancement of a penile erection by DA-8159 involved the relaxation of the cavernosal smooth muscle by NO-stimu-lated cGMP accumulation. In conclusion, DA-8159 is a selective inhibitor of PDE 5-catalyzed cGMP hydrolysis and the enhancement of a penile erection by DA-8159 is mediated by the relaxation of the cavernosal smooth muscle by the NO-stimulated cGMP accumulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson, K-E. and Wagner, G., Physiology of penile erection.Physiol. Rev., 75, 191–236 (1995).
Artemyev, O. A., Arshavsky, V. Y. and Cote, R. H., Photoreceptor phosphodiesterase: interaction of inhibitory gamma sub-unit and cyclic GMP with specific binding sites on catalytic subunits.Methods, 14, 93–104 (1998).
Azadzoi, K. M. and De Tajeda, I. S., Hypercholestrolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle.J. Urol., 146, 238–240 (1991).
Ballard, S. T., Gingell, C. J., Tang, K., Turner, L. A., Price, M. E. and Naylor A. M., Effects of Sildenafil on the relaxation of human corpus cavernosum tissu.in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.J. Urol., 159, 2164–2171 (1998).
Beavo, J. A., Cyclic nucleotide phophodiesterase: functional implications of multiple isoform.Physiol. Rev., 75, 725–748 (1995).
Burentt, A. L., Role of nitric oxide in the physiology of erection.Biol. Reprod., 52, 485–489 (1995).
Burnett, A. L., Lowenstein, C. J., Bredt, D. S., Chang, T S. K. and Snyder, S. H., Nitric oxide: a physiologic mediator of penile erection.Scinece, 257, 401–403 (1992).
Corbin, J. D. and Francis, S. H., Cyclic GMP phosphodieste-rase-5: target of sildenafil.J. Biol. Chem., 274, 13729–13732 (1999).
Corbin, J. D., Turko, I. V., Beasley, A. and Francis, S. H., Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.Eur. J. Biochem., 267, 2760–2767 (2000).
De Tajeda, I. S., Goldstein I., Adazoi, K., Krane, R. J. and Cohen, R. A., Impaired neurogenic and endothelium-me-diated relaxation of penile smooth muscle from diabetic men with impotence.N. Engl. J. Med., 320, 1025–1030 (1989).
Dishy, V., Sofowora, G., Harris, P. A., Kandcer, M., Zhan, F., Wood, A. J. and Stein, C. M., The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men.Clin. Pharmacol. Ther., 70 (3), 270–279 (2001).
Dousa, T. P., Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.Kidney Int., 55, 2962 (1999).
Ekholm, D., Belfrage, P., Manganiello, V. and Degerman, E., Protein kinase A-dependent activation of PDE4 (cAMP-specific nucleotide phosphodiesterase) in cultured bovine vascular smooth muscle cells.Biochim. Biophys. Acta, 1356, 6470 (1997).
Finberg, J. P. M., Levy, S. and Vardi, Y., Inhibition of nerve stimulation-induced vasodilation in corpora cavernosa of the pithed rat by blockade of nitric oxide synthetase.Br. J. Pharmacol., 108, 1038–1042 (1993).
Fink, T. L., Francis, S. H., Beasley, A., Grimes, K. A. and Corbin, J. D., Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5).J. Biol. Chem., 274, 34613–34620 (1999).
Freelish, M. and Noack, E., Correlation between nitric acid formation during degradation of organic nitrates and activation of guanylate cyclase.Eur. J. Pharmacol., 139, 19–30 (1987).
Gillespie, P. G., and Beavo J. A., Inhibition and stimulation of photoreceptor by dipyridamol and M&B.Mol. Pharm., 36, 773–781 (1989).
Hidaka, H. and Asano, T., Human blood platelet 3′: 5′-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase.Biochim. Biophys. Acta, 429, 485–497 (1976).
Hidaka, H. and Shibuya, M., A new assay of cyclic nucleotide phosphodiesterase; its application to human serum.Biochem. Med., 10, 301–311 (1974).
Hurley, J. B. and Stryer, L., Purification and characterization of the gamma regulatory subunit of the cyclic GMP phosphodiesterase from retinal rod outer segments.J. Biol. Chemistry, 257, 11094–11099 (1982).
Hurwitz, R. L., Bunt-Milam, A. H., Chang, M. L. and Beavo, J. A., cGMP phosphodiesterase in rod and cone outer segments of the retina.J. Mol. Biol., 260, 568–573 (1985).
Jeremy, J. Y., Ballard, S. A., Naylor, A. M., Miller, M. A. W. and Angelini, G. D., Effects of Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic Amp levels in the rabbit corpus cavernosu.in vitro. Br. J. Urol., 79, 958–963 (1997).
Lim, J., Pahlke, G. and Conti, M., Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation: identification and function of an inhibitory domain.J. Biol. Chem., 274, 19677–19685 (1999).
Lue, T. F., Hemodynamics of erection in the monkey.J. Urol., 130, 1237–1241 (1983).
Trigo-Rocha, F., Hsu, G. L., Donatucci, C. F. and Lue, T. F., The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncho-linergic, neurotranasmission in canine penile erection.J. Urol., 149, 872–877 (1993).
Wang, J. H., Teo, T S., Ho, H. C., and Stevens, F. S., Bovine heart protein activator of cyclic nucleotide phosphodiesterase.Adv. in Cyclic Nucleotide Res., 5., 179–194 (1975).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doh, H., Shin, C.Y., Son, M. et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 25, 873–878 (2002). https://doi.org/10.1007/BF02977007
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02977007